Last Post by dumbcritic 3 years ago
Topic starter 23/08/2020 6:42 pm
DRP-104 was designed as a novel prodrug of the broad acting glutamine antagonist DON (6-Diazo-5-oxo-L-norleucine). DRP-104 is inert in its prodrug form, affords high levels of plasma and GI tissue stability, has high tumour cell permeability and preferential tumour vs. plasma/GI tissue distribution for DON. Also, it synergizes with immune checkpoint blockade . A PhI trial should be open soon .